

Open Orphan Readmitted To AIM Following Reverse Takeover Of hVIVO


Open Orphan To Mount Compulsory Buyout To Get hVIVO Deal Over Line


UPDATE: Open Orphan To Relist On AIM Following hVIVO All-Share Merger


Open Orphan To Relist On AIM Following hVIVO All-Share Merger


(Sharecast News) - Drug consulting services platform Open Orphan has won a new three-year contract with an unnamed German pharmaceutical company.


Open Orphan Meets Acceptance Condition For Merger With hVIVO


UK Shareholder Meetings Calendar - Next 7 Days


(Sharecast News) - Europe-focussed rare and orphan drug consulting service provider Open Orphan announced the signing of a contract with SFA Therapeut...